Name: Sitravatinib (MGCD516)
Brand: Selleck Chemicals
SKU: S8573
Availability: InStock
Rating: 5 (10 reviews)

Jump to

Quality Control

Batch: Purity: 99.97%

99.97

Related Targets	EGFR VEGFR FGFR PDGFR c-Met Src MEK CSF-1R FLT3 HER2
Other c-Kit Inhibitors	Masitinib Amuvatinib (MP-470) OSI-930 PDGFR inhibitor 1 ISCK03 Masitinib mesylate AZD3229 Elenestinib phosphate M4205（IDRX-42） Bezuclastinib

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Activity Description	PMID
KB-8-5-11	qHTS assay	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen, Potency = 4.6109 μM.	31515284
KB-3-1	qHTS assay	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	31515284
Click to View More Cell Line Experimental Data

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (158.81 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 100 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5.000mg/ml (7.94mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.830mg/ml (1.32mM)	Taking the 1 mL working solution as an example, add 50 μL of 16.6 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	629.68	Formula	C₃₃H₂₉F₂N₅O₄S	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	1123837-84-2	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	MG-516			SMILES	COCCNCC1=CN=C(C=C1)C2=CC3=NC=CC(=C3S2)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	DDR2 (Cell-free assay) 0.5 nM EPHA3 (Cell-free assay) 1 nM Axl (Cell-free assay) 1.5 nM Mer (Cell-free assay) 2 nM VEGFR3 (FLT4) (Cell-free assay) 2 nM VEGFR2 (KDR) (Cell-free assay) 5 nM TRKA (NTRK1) (Cell-free assay) 5 nM VEGFR1 (FLT1) (Cell-free assay) 6 nM Kit (Cell-free assay) 6 nM FLT3 (Cell-free assay) 8 nM TRKB (NTRK2) (Cell-free assay) 9 nM EPHB2 (Cell-free assay) 10 nM EPHB4 (Cell-free assay) 12 nM Met (Cell-free assay) 20 nM DDR1 (Cell-free assay) 29 nM PDGFRα (Cell-free assay) 30 nM RON (Cell-free assay) 43 nM RET (Cell-free assay) 44 nM EphA2 (Cell-free assay) 44 nM ROS (Cell-free assay) 59 nM EPHA4 (Cell-free assay) 76 nM Src (Cell-free assay) 156 nM
In vitro	Sitravatinib (MGCD516) is an oral, potent small molecule inhibitor of a closely related spectrum of RTKs including RET, the split RTKs (VEGFR, PDGFR and KIT), TRK family, DDR2, MET and AXL. Treatment with this compound resulted in significant blockade of phosphorylation of potential driver RTKs and induced potent anti-proliferative effects in vitro.
In vivo	Sitravatinib (MGCD516) has demonstrated antitumor activity in nonclinical cancer models harboring genetic alterations of its targets, including rearrangement of RET, NTRK, or CHR4q12 amplification. Treatment of tumor xenografts in vivo with this compound resulted in significant suppression of tumor growth.
References	[1] http://www.jto.org/article/S1556-0864(16)32735-6/pdf [2] https://pubmed.ncbi.nlm.nih.gov/26675259/

Applications

Methods	Biomarkers	Images	PMID
Growth inhibition assay	Cell viability		26675259
Western blot	p-IGF1-R / IGF1-R / p-PDGFRβ / PDGFRβ/ p-AKT / AKT		26675259

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2023-06-07)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05564338	WITHDRAWN	Hepatocellular Carcinoma	BeiGene	2023-06-30	PHASE3
NCT05407519	UNKNOWN	Hepatocellular Carcinoma	Anhui Provincial Hospital	2022-07-25	PHASE2
NCT04164199	COMPLETED	Advanced Malignancies	BeOne Medicines	2019-12-19	PHASE3
NCT04904302	TERMINATED	Advanced Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v8	M.D. Anderson Cancer Center	2022-05-03	PHASE2
NCT05419817	WITHDRAWN	Recurrent Endometrial Cancer; Solid Tumors	Haider Mahdi	2022-09-08	PHASE2
NCT04887870	COMPLETED	Advanced or Metastatic Solid Malignancies	Mirati Therapeutics Inc.	2021-06-29	PHASE2; PHASE3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Sitravatinib (MGCD516) c-Kit inhibitor

Chemical Structure

Molecular Weight: 629.68